Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Hookipa Pharma ( (HOOK) ).
On July 18, 2025, HOOKIPA Pharma Inc. announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market and deregister under the Securities Exchange Act of 1934. This decision follows an asset purchase agreement with Gilead Sciences, Inc., where Gilead will acquire assets related to HOOKIPA’s HB-400 and HB-500 programs. The delisting and deregistration are part of HOOKIPA’s strategic plan to dissolve and liquidate, pending stockholder approval at a special meeting on July 29, 2025. The move is aimed at reducing compliance costs and maximizing asset distribution to stockholders.
The most recent analyst rating on (HOOK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.
Spark’s Take on HOOK Stock
According to Spark, TipRanks’ AI Analyst, HOOK is a Neutral.
Hookipa Pharma’s overall stock score is driven by substantial financial difficulties, negative valuation metrics, and bearish technical indicators. The absence of earnings call insights or corporate events further limits positive outlooks. The company faces a challenging environment with a critical need for strategic improvements.
To see Spark’s full report on HOOK stock, click here.
More about Hookipa Pharma
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapeutics based on its proprietary arenavirus platform. The company’s product candidates aim to induce specific, robust, and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. HOOKIPA’s pipeline includes therapies for oncology, targeting HPV16+ cancers, KRAS mutated cancers, and other targets. Additionally, HOOKIPA has partnered with Gilead Sciences, Inc. to develop therapies for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
Average Trading Volume: 125,742
Technical Sentiment Signal: Sell
Current Market Cap: $13.91M
Learn more about HOOK stock on TipRanks’ Stock Analysis page.